Logo image of APLS

APELLIS PHARMACEUTICALS INC (APLS) Stock Fundamental Analysis

NASDAQ:APLS - Nasdaq - US03753U1060 - Common Stock - Currency: USD

19.91  +0.47 (+2.42%)

After market: 19.91 0 (0%)

Fundamental Rating

3

APLS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. APLS may be in some trouble as it scores bad on both profitability and health. APLS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year APLS has reported negative net income.
In the past year APLS has reported a negative cash flow from operations.
APLS had negative earnings in each of the past 5 years.
APLS had a negative operating cash flow in each of the past 5 years.
APLS Yearly Net Income VS EBIT VS OCF VS FCFAPLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

APLS has a Return On Assets of -27.71%. This is in the better half of the industry: APLS outperforms 70.43% of its industry peers.
APLS has a Return On Equity of -136.21%. This is in the lower half of the industry: APLS underperforms 60.39% of its industry peers.
Industry RankSector Rank
ROA -27.71%
ROE -136.21%
ROIC N/A
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
APLS Yearly ROA, ROE, ROICAPLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

With an excellent Gross Margin value of 83.00%, APLS belongs to the best of the industry, outperforming 87.28% of the companies in the same industry.
APLS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for APLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
APLS Yearly Profit, Operating, Gross MarginsAPLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

APLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APLS has been increased compared to 1 year ago.
Compared to 5 years ago, APLS has more shares outstanding
The debt/assets ratio for APLS has been reduced compared to a year ago.
APLS Yearly Shares OutstandingAPLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
APLS Yearly Total Debt VS Total AssetsAPLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -2.13, we must say that APLS is in the distress zone and has some risk of bankruptcy.
APLS's Altman-Z score of -2.13 is in line compared to the rest of the industry. APLS outperforms 53.23% of its industry peers.
A Debt/Equity ratio of 2.76 is on the high side and indicates that APLS has dependencies on debt financing.
APLS has a Debt to Equity ratio of 2.76. This is amonst the worse of the industry: APLS underperforms 81.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.76
Debt/FCF N/A
Altman-Z -2.13
ROIC/WACCN/A
WACC9.66%
APLS Yearly LT Debt VS Equity VS FCFAPLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

2.3 Liquidity

A Current Ratio of 4.08 indicates that APLS has no problem at all paying its short term obligations.
APLS's Current ratio of 4.08 is in line compared to the rest of the industry. APLS outperforms 46.59% of its industry peers.
A Quick Ratio of 3.62 indicates that APLS has no problem at all paying its short term obligations.
APLS has a Quick ratio (3.62) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.08
Quick Ratio 3.62
APLS Yearly Current Assets VS Current LiabilitesAPLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.01% over the past year.
APLS shows a strong growth in Revenue. In the last year, the Revenue has grown by 48.03%.
Measured over the past years, APLS shows a very strong growth in Revenue. The Revenue has been growing by 127.23% on average per year.
EPS 1Y (TTM)47.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.19%
Revenue 1Y (TTM)48.03%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%-3.21%

3.2 Future

The Earnings Per Share is expected to grow by 31.59% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 16.21% on average over the next years. This is quite good.
EPS Next Y-21.41%
EPS Next 2Y23.32%
EPS Next 3Y36%
EPS Next 5Y31.59%
Revenue Next Year7.87%
Revenue Next 2Y10.81%
Revenue Next 3Y14.62%
Revenue Next 5Y16.21%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
APLS Yearly Revenue VS EstimatesAPLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
APLS Yearly EPS VS EstimatesAPLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

APLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APLS Price Earnings VS Forward Price EarningsAPLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APLS Per share dataAPLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

APLS's earnings are expected to grow with 36.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.32%
EPS Next 3Y36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for APLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APELLIS PHARMACEUTICALS INC

NASDAQ:APLS (7/14/2025, 8:23:11 PM)

After market: 19.91 0 (0%)

19.91

+0.47 (+2.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners102.48%
Inst Owner Change0%
Ins Owners3.77%
Ins Owner Change1.48%
Market Cap2.50B
Analysts77.86
Price Target36.08 (81.22%)
Short Float %23.58%
Short Ratio10
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-37.55%
Min EPS beat(2)-101.36%
Max EPS beat(2)26.26%
EPS beat(4)2
Avg EPS beat(4)-27.55%
Min EPS beat(4)-101.36%
Max EPS beat(4)26.26%
EPS beat(8)4
Avg EPS beat(8)-14.05%
EPS beat(12)5
Avg EPS beat(12)-11.13%
EPS beat(16)5
Avg EPS beat(16)-14.48%
Revenue beat(2)1
Avg Revenue beat(2)-5.68%
Min Revenue beat(2)-16.4%
Max Revenue beat(2)5.05%
Revenue beat(4)2
Avg Revenue beat(4)-3.15%
Min Revenue beat(4)-16.4%
Max Revenue beat(4)5.05%
Revenue beat(8)5
Avg Revenue beat(8)4.07%
Revenue beat(12)7
Avg Revenue beat(12)7.23%
Revenue beat(16)10
Avg Revenue beat(16)41.69%
PT rev (1m)-1.21%
PT rev (3m)-17.85%
EPS NQ rev (1m)-0.21%
EPS NQ rev (3m)-81.41%
EPS NY rev (1m)9.36%
EPS NY rev (3m)-75.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.35%
Revenue NY rev (1m)6.71%
Revenue NY rev (3m)-4.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.23
P/FCF N/A
P/OCF N/A
P/B 15.24
P/tB 15.24
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS6.17
BVpS1.31
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.71%
ROE -136.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83%
FCFM N/A
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
F-Score4
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 2.76
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.56%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.08
Quick Ratio 3.62
Altman-Z -2.13
F-Score4
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)54.61%
Cap/Depr(5y)218.08%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.19%
EPS Next Y-21.41%
EPS Next 2Y23.32%
EPS Next 3Y36%
EPS Next 5Y31.59%
Revenue 1Y (TTM)48.03%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%-3.21%
Revenue Next Year7.87%
Revenue Next 2Y10.81%
Revenue Next 3Y14.62%
Revenue Next 5Y16.21%
EBIT growth 1Y53.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.6%
EBIT Next 3Y47.79%
EBIT Next 5Y41.5%
FCF growth 1Y98.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y98.57%
OCF growth 3YN/A
OCF growth 5YN/A